Semaglutide
5 mg
$39.00
Retatrutide 10 mg + Cagrilintide 2.5 mg combo blend, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
For use by licensed and trained professionals only, operating within their applicable regulations. Not evaluated by the FDA.
Retatrutide 10 mg + Cagrilintide 2.5 mg combo blend, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 10 mg + 2.5 mg — $129.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 4731.3 / 4409.0 g/mol |
| CAS | 2381089-83-2 / 1415456-99-3 |
| Sequence length | — |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | GLP-RETACAGRI-102.5 |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
This blend pairs two investigational compounds from different manufacturers' pipelines — Lilly's triple-agonist retatrutide and Novo Nordisk's amylin analogue cagrilintide — into a single research vial. It does not correspond to a specific branded clinical-trial arm from either company; it is a research formulation combining two independently studied mechanisms.
The rationale mirrors the logic behind CagriSema: pairing a GLP-1-pathway agonist with an amylin-receptor agonist to act on complementary appetite-regulation circuits. Retatrutide additionally contributes GIP and glucagon receptor activity, making this combination mechanistically broader than either compound alone — though there is no dedicated clinical-trial dataset for this specific four-receptor combination.
Used in research settings to compare four-pathway (GLP-1/GIP/glucagon/amylin) engagement against the individual compounds and against two-pathway combinations like CagriSema.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
Not as a named combination product — retatrutide and cagrilintide have separate clinical-trial programs from different manufacturers. This vial combines the two compounds for research purposes; there is no dedicated trial dataset for this specific pairing.
Further reading: for the published preclinical and clinical literature on Retatrutide + Cagrilintide, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.